234 related articles for article (PubMed ID: 32022878)
1. Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States.
Mahase SS; D'Angelo D; Kang J; Hu JC; Barbieri CE; Nagar H
JAMA Netw Open; 2020 Feb; 3(2):e1920471. PubMed ID: 32022878
[TBL] [Abstract][Full Text] [Related]
2. Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US.
Washington SL; Jeong CW; Lonergan PE; Herlemann A; Gomez SL; Carroll PR; Cooperberg MR
JAMA Netw Open; 2020 Dec; 3(12):e2031349. PubMed ID: 33369661
[TBL] [Abstract][Full Text] [Related]
3. Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer.
Bagley AF; Anscher MS; Choi S; Frank SJ; Hoffman KE; Kuban DA; McGuire SE; Nguyen QN; Chapin B; Aparicio A; Pezzi TA; Smith GL; Smith BD; Hess K; Tang C
JAMA Netw Open; 2020 Mar; 3(3):e201255. PubMed ID: 32191331
[TBL] [Abstract][Full Text] [Related]
4. Differential Use of Radiotherapy Fractionation Regimens in Prostate Cancer.
Qureshy SA; Diven MA; Ma X; Marciscano AE; Hu JC; McClure TD; Barbieri C; Nagar H
JAMA Netw Open; 2023 Oct; 6(10):e2337165. PubMed ID: 37815829
[TBL] [Abstract][Full Text] [Related]
5. Travel distance and stereotactic body radiotherapy for localized prostate cancer.
Mahal BA; Chen YW; Sethi RV; Padilla OA; Yang DD; Chavez J; Muralidhar V; Hu JC; Feng FY; Hoffman KE; Martin NE; Spratt DE; Yu JB; Orio PF; Nguyen PL
Cancer; 2018 Mar; 124(6):1141-1149. PubMed ID: 29231964
[TBL] [Abstract][Full Text] [Related]
6. Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018.
Parikh RB; Robinson KW; Chhatre S; Medvedeva E; Cashy JP; Veera S; Bauml JM; Fojo T; Navathe AS; Malkowicz SB; Mamtani R; Jayadevappa R
JAMA Netw Open; 2020 Sep; 3(9):e2018318. PubMed ID: 32986109
[TBL] [Abstract][Full Text] [Related]
7. National practice patterns and time trends in androgen ablation for localized prostate cancer.
Cooperberg MR; Grossfeld GD; Lubeck DP; Carroll PR
J Natl Cancer Inst; 2003 Jul; 95(13):981-9. PubMed ID: 12837834
[TBL] [Abstract][Full Text] [Related]
8. Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer.
Gray PJ; Lin CC; Cooperberg MR; Jemal A; Efstathiou JA
Eur Urol; 2017 May; 71(5):729-737. PubMed ID: 27597241
[TBL] [Abstract][Full Text] [Related]
9. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
[TBL] [Abstract][Full Text] [Related]
10. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer.
Borno HT; Lichtensztajn DY; Gomez SL; Palmer NR; Ryan CJ
Cancer; 2019 Feb; 125(3):453-462. PubMed ID: 30444526
[TBL] [Abstract][Full Text] [Related]
11. Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
J Racial Ethn Health Disparities; 2019 Feb; 6(1):133-142. PubMed ID: 29959759
[TBL] [Abstract][Full Text] [Related]
12. National Trends in the Utilization of Androgen Deprivation Therapy for Very Low Risk Prostate Cancer.
May A; Henke J; Au D; Raza SJ; Davaro F; Hamilton Z; Siddiqui SA
Urology; 2019 Aug; 130():79-85. PubMed ID: 31047912
[TBL] [Abstract][Full Text] [Related]
13. Increasing Use of Shorter-Course Radiotherapy for Prostate Cancer.
Yu JB; Sun Y; Jia AY; Vince RA; Shoag JE; Zaorsky NG; Spratt DE
JAMA Oncol; 2023 Dec; 9(12):1696-1701. PubMed ID: 37796479
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Demographic Factors Associated With Receipt of Non Guideline-concordant Initial Therapy for Nonmetastatic Prostate Cancer.
Hamilton AS; Fleming ST; Wang D; Goodman M; Wu XC; Owen JB; Lo M; Ho A; Anderson RT; Thompson T
Am J Clin Oncol; 2016 Feb; 39(1):55-63. PubMed ID: 24390274
[TBL] [Abstract][Full Text] [Related]
15. Trends and black/white differences in treatment for nonmetastatic prostate cancer.
Klabunde CN; Potosky AL; Harlan LC; Kramer BS
Med Care; 1998 Sep; 36(9):1337-48. PubMed ID: 9749657
[TBL] [Abstract][Full Text] [Related]
16. Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population.
Lichtensztajn DY; Leppert JT; Brooks JD; Shah SA; Sieh W; Chung BI; Gomez SL; Cheng I
J Natl Compr Canc Netw; 2018 Nov; 16(11):1353-1360. PubMed ID: 30442735
[No Abstract] [Full Text] [Related]
17. Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.
Kishan AU; Dang A; Katz AJ; Mantz CA; Collins SP; Aghdam N; Chu FI; Kaplan ID; Appelbaum L; Fuller DB; Meier RM; Loblaw DA; Cheung P; Pham HT; Shaverdian N; Jiang N; Yuan Y; Bagshaw H; Prionas N; Buyyounouski MK; Spratt DE; Linson PW; Hong RL; Nickols NG; Steinberg ML; Kupelian PA; King CR
JAMA Netw Open; 2019 Feb; 2(2):e188006. PubMed ID: 30735235
[TBL] [Abstract][Full Text] [Related]
18. Income inequality and treatment of African American men with high-risk prostate cancer.
Ziehr DR; Mahal BA; Aizer AA; Hyatt AS; Beard CJ; D Amico AV; Choueiri TK; Elfiky A; Lathan CS; Martin NE; Sweeney CJ; Trinh QD; Nguyen PL
Urol Oncol; 2015 Jan; 33(1):18.e7-18.e13. PubMed ID: 25306287
[TBL] [Abstract][Full Text] [Related]
19. Radiation Facility Volume and Survival for Men With Very High-Risk Prostate Cancer Treated with Radiation and Androgen Deprivation Therapy.
Sebastian N; Goyal S; Liu Y; Janopaul-Naylor JR; Patel PR; Dhere VR; Hanasoge S; Shelton JW; Godette KD; Jani AB; Hershatter B; Fischer-Valuck B; Patel SA
JAMA Netw Open; 2023 Aug; 6(8):e2327637. PubMed ID: 37552479
[TBL] [Abstract][Full Text] [Related]
20. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
